ICAP at Columbia University, New York, NY.
Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.
J Acquir Immune Defic Syndr. 2018 Aug 15;78 Suppl 2:S134-S141. doi: 10.1097/QAI.0000000000001739.
Remarkable success in the prevention and treatment of pediatric HIV infection has been achieved in the past decade. Large differences remain between the estimated number of children living with HIV (CLHIV) and those identified through national HIV programs. We evaluated the number of CLHIV and those on treatment in Lesotho, Malawi, Swaziland, Tanzania, Uganda, Zambia, and Zimbabwe.
We assessed the total number of CLHIV, CLHIV on antiretroviral treatment (ART), and national and regional ART coverage gaps using 3 data sources: (1) Joint United Nations Programme on HIV/AIDS model-based estimates and national program data used as input values in the models, (2) population-based HIV impact surveys (PHIA), and (3) program data from the President's Emergency Plan for AIDS Relief (PEPFAR)-supported clinics.
Across the 7 countries, HIV prevalence among children aged 0-14 years ranged from 0.4% (Uncertainty Bounds (UB) 0.2%-0.6%) to 2.8% (UB: 2.2%-3.4%) according to the PHIA surveys, resulting in estimates of 520,000 (UB: 460,000-580,000) CLHIV in 2016-2017 in the 7 countries. This compared with Spectrum estimates of pediatric HIV prevalence ranging from 0.5% (UB: 0.5%-0.6%) to 3.5% (UB: 3.0%-4.0%) representing 480,000 (UB: 390,000-550,000) CLHIV. CLHIV not on treatment according to the PEPFAR, PHIA, and Spectrum for the countries stood at 48% (UB: 25%-60%), 49% (UB: 37%-50%), and 38% (UB: 24%-47%), respectively. Of 78 regions examined across 7 countries, 33% of regions (PHIA data) or 41% of regions (PEPFAR data) had met the ART coverage target of 81%.
There are substantial gaps in the coverage of HIV treatment in CLHIV in the 7 countries studied according to all sources. There is continued need to identify, engage, and treat infants and children. Important inconsistencies in estimates across the 3 sources warrant in-depth investigation.
在过去的十年中,儿科 HIV 感染的预防和治疗取得了显著的成功。估计的儿童 HIV 感染者(CLHIV)数量与通过国家 HIV 项目发现的数量之间仍然存在很大差异。我们评估了莱索托、马拉维、斯威士兰、坦桑尼亚、乌干达、赞比亚和津巴布韦的 CLHIV 数量和接受治疗的数量。
我们使用 3 种数据源评估了 CLHIV 的总数、接受抗逆转录病毒治疗(ART)的 CLHIV 数量以及国家和地区的 ART 覆盖差距:(1)联合联合国艾滋病毒/艾滋病规划署基于模型的估计数和作为模型输入值的国家方案数据;(2)基于人群的艾滋病毒影响调查(PHIA);(3)总统艾滋病紧急救援计划(PEPFAR)支持诊所的方案数据。
根据 PHIA 调查,7 个国家 0-14 岁儿童的 HIV 流行率范围为 0.4%(UB:0.2%-0.6%)至 2.8%(UB:2.2%-3.4%),这导致 2016-2017 年 7 个国家的 CLHIV 估计数为 52 万(UB:46 万-58 万)。这与 Spectrum 估计的儿科 HIV 流行率(0.5%,UB:0.5%-0.6%至 3.5%,UB:3.0%-4.0%)形成对比,代表 48 万(UB:39 万-55 万)CLHIV。根据 PEPFAR、PHIA 和 Spectrum,未接受治疗的 CLHIV 分别占各国的 48%(UB:25%-60%)、49%(UB:37%-50%)和 38%(UB:24%-47%)。在 7 个国家检查的 78 个地区中,33%的地区(PHIA 数据)或 41%的地区(PEPFAR 数据)达到了 81%的 ART 覆盖目标。
根据所有来源,7 个研究国家的 CLHIV 接受 HIV 治疗的覆盖率存在很大差距。仍然需要确定、接触和治疗婴儿和儿童。3 个来源之间的估计存在重要差异,需要进行深入调查。